百利天恒公告,公司自主研发的全球首创EGFR×HER3双抗ADC药物iza-bren在治疗局部晚期或转移性鼻咽癌的III期临床试验中,期中分析达到主要终点。该药物已在40余项临床试验中展现出治疗多种肿瘤的潜力,并有5项适应症被纳入国家药品监督管理局突破性治疗品种名单。公司将按有关规定积极推进研发项目,并及时披露进展情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.